” This study includes proof of real-world Moderna COVID-19 vaccine efficiency, especially among the general population,” stated Hung Fu Tseng, PhD, a researcher with the Kaiser Permanente Southern California Department of Research & & Evaluation and the senior author of the study. “Additionally, our follow-up on these fully vaccinated patients happened through June 2021, a period that overlapped with the emergence of the delta variant in the United States. Long-lasting follow-up is continuous to further examine the sturdiness of defense.”
Reference: “Real-world efficiency of the mRNA-1273 vaccine against COVID-19: Interim results from a potential observational mate study” by Katia J. Bruxvoort, Lina S. Sy, Lei Qian, Bradley K. Ackerson, Yi Luo, Gina S. Lee, Yun Tian, Ana Florea, Harpreet S. Takhar, Julia E. Tubert, Carla A. Talarico and Hung Fu Tseng, 25 November 2021, The Lancet Regional Health– Americas.DOI: 10.1016/ j.lana.2021.100134.
The study was moneyed by Moderna, Inc
.
” This research study provides encouraging proof of the high effectiveness of the Moderna COVID-19 vaccine in avoiding infection, hospitalization, and death from COVID-19,” said Katia Bruxvoort, PhD, an adjunct private investigator with the Kaiser Permanente Southern California Department of Research & & Evaluation.” One of the essential elements of this study was that it consisted of more than 700,000 grownups who were racially and ethnically diverse and had a broad variety of underlying conditions including persistent diseases, immunocompromising conditions, and autoimmune conditions.”
This study evaluated the 5-month efficiency of the Moderna COVID-19 mRNA vaccine as part of a 5-year observational research study within Kaiser Permanente, an integrated healthcare organization with 4.7 million members in Southern California.
The study included 352,878 receivers of 2 dosages of Moderna COVID-19 vaccine matched to 352,878 unvaccinated individuals by age, sex, race, and ethnic culture. Immunized individuals got 2 doses of Moderna COVID-19 vaccine from December 18, 2020, to March 31, 2021. People in both groups were followed till June 30, 2021.
Kaiser Permanente research study reveals Moderna COVID-19 vaccine is 87% reliable in preventing COVID-19 infection, and more than 95% reliable in avoiding extreme COVID-19.
Kaiser Permanente research study in Southern California released November 25, 2021, in The Lancet Regional Health– Americas validated high Moderna COVID-19 vaccine efficiency as much as 5 months after the 2nd dose. Effectiveness was 87% against COVID-19 infection, 96% versus COVID-19 hospitalization, and 98% versus COVID-19 death.
“Additionally, our follow-up on these totally immunized patients happened through June 2021, a duration that overlapped with the introduction of the delta variant in the United States.
The study consisted of 352,878 receivers of 2 doses of Moderna COVID-19 vaccine matched to 352,878 unvaccinated people by age, ethnic culture, race, and sex. Vaccinated people got 2 doses of Moderna COVID-19 vaccine from December 18, 2020, to March 31, 2021. People in both groups were followed until June 30, 2021.
During follow-up, COVID-19 infections happened amongst 289 immunized clients and 1,144 unvaccinated clients. Vaccine efficiency against COVID-19 infection was 87%.
COVID-19 hospitalization happened amongst 13 immunized and 182 unvaccinated patients, and COVID-19 in-hospital deaths happened amongst 1 vaccinated and 25 unvaccinated clients. Vaccine effectiveness against COVID-19 hospitalization was 96%, and vaccine efficiency against COVID-19 in-hospital deaths was 98%.
Vaccine efficiency against COVID-19 infection stayed high across age, sex, racial, and ethnic subgroups, with outcomes varying from 83% to 92%.
Vaccine effectiveness was greater versus symptomatic COVID-19 (88%) than asymptomatic COVID-19 (73%).
From March to June 2021, there were 5,619 SARS-CoV-2 favorable specimens that were effectively sequenced. The most prevalent variations were alpha (42%), epsilon (18%), delta (12%), and gamma (9%), with delta increasing to 54% of versions by June 2021.